Article thumbnail

Adjusted hazard ratios for 1-year clinical outcomes by proportion of time in therapeutic range for the main analysis and sensitivity analysis (excluding international normalised ratio readings and events during the first 3 months of treatment).

By Sylvia Haas (414005), Hugo ten Cate (280615), Gabriele Accetta (3280818), Pantep Angchaisuksiri (3280821), Jean-Pierre Bassand (414002), A. John Camm (480892), Ramon Corbalan (3280824), Harald Darius (78727), David A. Fitzmaurice (414003), Samuel Z. Goldhaber (414004), Shinya Goto (82609), Barry Jacobson (3280827), Gloria Kayani (414012), Lorenzo G. Mantovani (414007), Frank Misselwitz (414010), Karen Pieper (3280815), Sebastian M. Schellong (3280809), Janina Stepinska (3280812), Alexander G. G. Turpie (414008), Martin van Eickels (414009) and Ajay K. Kakkar (414000)

Abstract

<p>Adjusted hazard ratios for 1-year clinical outcomes by proportion of time in therapeutic range for the main analysis and sensitivity analysis (excluding international normalised ratio readings and events during the first 3 months of treatment).</p

Topics: Medicine, Neuroscience, Physiology, Developmental Biology, Cancer, Mental Health, Chemical Sciences not elsewhere classified, Vitamin K antagonists, GARFIELD-AF, TTR, 1- year follow-up, 1- Year Outcomes, VKA control, Vitamin K Antagonist Control, INR, SE, stroke, AF, NCT, all-cause mortality, 1- year outcomes
Year: 2016
DOI identifier: 10.1371/journal.pone.0164076.t005
OAI identifier: oai:figshare.com:article/4127454
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://figshare.com/articles/... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.